Literature DB >> 22820191

The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells.

Xianwei Wang1, Jianfeng Zhao, Jianhua Huang, Huihuan Tang, Shuyi Yu, Yuxiang Chen.   

Abstract

Carcinogenesis is driven by an accumulation of mutations and genetic lesions, which leads to activation of oncogenes and inactivation of tumor suppressor genes. However, the molecular mechanisms by which the expression of these genes was regulated in pancreatic cancer remains unclear. In this study, we investigated the regulatory effects of microRNA and methylation on the expression of k-ras, TP53 and PTEN genes in pancreatic cancer cells. The protein and miRNA levels were measured by Western blotting and Northern blotting, respectively. Xenograft pancreatic tumor models were established by inoculating BxPC-1, Capan-2, and Panc-1 tumor cells into athymic nu/nu mice. A disparate level of KRAS, p53, PTEN, Dnmts, and Dicer 1 proteins as well as let-7i, miR-22, miR-143, and miR-29b miRNA was observed in BxPC-1, Capan-2, and Panc-1 cells. Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression. Knockdown of Dicer 1 expression in Capan-2 cells significantly increased p53 and PTEN expression, while significantly decreased miR-22 and miR-143 expression, but had no effects on PTEN, Dnmts, let-7i, and miR-29b expression. Knockdown of Dicer 1 expression significantly inhibited xenograft BxPC-3 tumor growth, but promoted xenograft Panc-1 tumor growth. In contrast, knockdown of Dicer 1 expression had no effect on xenograft Capan-2 tumor growth. Our study suggested that different pancreatic cancer cell lines exhibited obvious discrepancies in gene expression profiles, implying that different molecular mechanisms are involved in the carcinogenesis of pancreatic cancer subclasses. Our study highlighted the importance of personalized therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820191     DOI: 10.1016/j.bbrc.2012.07.047

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Epigenetic inactivation of miR-203 as a key step in neural crest epithelial-to-mesenchymal transition.

Authors:  Estefanía Sánchez-Vásquez; Marianne E Bronner; Pablo H Strobl-Mazzulla
Journal:  Development       Date:  2019-04-11       Impact factor: 6.868

2.  The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.

Authors:  Yunpeng Sun; Pengfei Wang; Wenjun Yang; Yunfeng Shan; Qiyu Zhang; Huanhuan Wu
Journal:  Cancer Biol Ther       Date:  2019-03-27       Impact factor: 4.742

3.  Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer.

Authors:  Ganepola Ap Ganepola; John R Rutledge; Paritosh Suman; Anusak Yiengpruksawan; David H Chang
Journal:  World J Gastrointest Oncol       Date:  2014-01-15

Review 4.  Epigenetic deregulations in chordoma.

Authors:  Xin Yu; Zheng Li
Journal:  Cell Prolif       Date:  2015-08-10       Impact factor: 6.831

Review 5.  miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review.

Authors:  Bárbara Alemar; Cleandra Gregório; Patricia Ashton-Prolla
Journal:  Biomark Insights       Date:  2015-12-13

6.  Protamine nanoparticles for improving shRNA-mediated anti-cancer effects.

Authors:  Ming Liu; Bo Feng; Yijie Shi; Chang Su; Huijuan Song; Wei Cheng; Liang Zhao
Journal:  Nanoscale Res Lett       Date:  2015-03-19       Impact factor: 4.703

7.  Dicer regulates differentiation and viability during mouse pancreatic cancer initiation.

Authors:  John P Morris; Renee Greer; Holger A Russ; Guido von Figura; Grace E Kim; Anke Busch; Jonghyeob Lee; Klemens J Hertel; Seung Kim; Michael McManus; Matthias Hebrok
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

8.  Identification of Circulating Serum miRNAs as Novel Biomarkers in Pancreatic Cancer Using a Penalized Algorithm.

Authors:  Jaehoon Lee; Hee Seung Lee; Soo Been Park; Chanyang Kim; Kahee Kim; Dawoon E Jung; Si Young Song
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

9.  Detection of Differentially Expressed MicroRNAs in Rheumatic Heart Disease: miR-1183 and miR-1299 as Potential Diagnostic Biomarkers.

Authors:  Ni Li; Jiangfang Lian; Sheng Zhao; Dawei Zheng; Xi Yang; Xiaoyan Huang; Xinbao Shi; Lebo Sun; Qingyun Zhou; Huoshun Shi; Guodong Xu; Enchill KoJo Incoom; Jianqing Zhou; Guofeng Shao
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

10.  Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Qian Jiang; Xiaojing Lu; Pengli Huang; Chao Gao; Xiaoxi Zhao; Tianyu Xing; Gang Li; Shilai Bao; Huyong Zheng
Journal:  Biomed Res Int       Date:  2018-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.